Trial Profile
Retreatment study of patients with non-Hodgkin's lymphoma who have previously responded to iodine-131 anti-B1 antibody [iodine-131 tositumomab]
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 25 Sep 2005 New trial record.